Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

690 results about "Proliferative disease" patented technology

Proliferative kidney disease (PKD) is an endoparasitic disease of salmonid fish caused by Tetracapsuloides bryosalmonae (Myxozoa: Malacosporea). This chronic, largely renal interstitial disease is caused by the extraporogonic but intracellular stages of the parasite, which cause a severe granulomatous host response.

Combination containing an mRNA vaccine or an mRNA encoded therapeutic protein and an immune modulating mRNA for improved or reduced immunogenicity to increase efficacy

The present invention pertains to a combination comprising two or more mRNA molecules, or a single mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule, wherein the combination comprises at least one first mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and at least one second mRNA molecule encoding a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule. The invention also relates to a host cell comprising a combination or the single mRNA molecule according to the present invention, a pharmaceutical composition comprising the combination, the single mRNA molecule, or the host cell of the present invention, and a vaccine comprising the combination, the single mRNA molecule, the host cell, or the pharmaceutical composition according to the present invention. Further provided is a kit comprising the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, or the vaccine according to the present invention. The invention also pertains to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in medicine. Finally, the invention also relates to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in a method of prevention, and / or treatment of an infectious, a genetic, or a proliferative disease.
Owner:IMGEN-T-SRL

Dual payload antibody drug conjugates

The present disclosure is related to dual payload antibody drug conjugates comprising at least one topoisomerase inhibitor and at least one DNA Damage Response (DDR) inhibitor, pharmaceutical compositions thereof, and the use of the antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases.
Owner:SUTRO BIOPHARMA INC

Sting agonist immunostimulatory antibody drug conjugates

The present disclosure is related to dual payload immunostimulatory antibody drug conjugates comprising at least STING agonist and at least one cytotoxic agent, pharmaceutical compositions thereof, and the use of the dual payload immunostimulatory antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases.
Owner:ASTELLAS PHARMA INC

Phosphatidylinositol proteoglycan 3 antibodies and related methods

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.
Owner:JIECO BIOPHARMACEUTICALS

A niclosamide containing compound for the treatment of proliferative diseases and modulation of the immune system

PCT designated stageWO2025095912A2Organic active ingredientsDiseaseProteasome Inhibition
The invention relates to the field of 26S proteasome inhibition and modulation by niclosamide and to a method for treating diseases related to increased proliferation, immune system, inflammation and neurodegenerative disorders by inhibition and modulation of the 26S proteasome in living cells, and to a niclosamide-containing compound for use in this treatment.
Owner:T C ANKARA UNIVERSITESI REKTORLUGU

Antibody-drug conjugates and uses thereof

The present invention relates to antibody-drug conjugates wherein the antibody specifically binds to folate receptor alpha, and wherein the drug is preferably selected from cytotoxic drugs. Such antibody-drug conjugates are particularly useful for the treatment of proliferative diseases including cancers such as ovarian cancer, breast cancer and non-small cell lung cancer.
Owner:MABLINK BIOSCIENCE SAS

Cucurbituril compound and medical application thereof

The invention relates to a cucurbituril compound and medical application thereof. Specifically, the invention relates to a compound as shown in a formula (I) and a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound and application thereof as a therapeutic agent, especially application in treatment or prevention of proliferative diseases, cardiovascular related diseases or hematologic cancers, use in reversing drug-induced neuromuscular block and / or anesthesia. I) # imgabs0 #
Owner:SHANGHAI SENHUI MEDICINE CO LTD +2

Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response

Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and / or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and / or adaptive immune response), and are useful in treating and / or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Owner:CHILDRENS MEDICAL CENT CORP +1

Salt and crystal form of a FAK inhibitor

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula I below, and the use of that inhibitor for treating a proliferative disease:
Owner:AMPLIA THERAPEUTICS LTD

CD3 / BCMA / CD38 trispecific antibodies

The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically, the present invention relates to trispecific heterodimeric immunoglobulins that target a human CD3 antigen, a human BCMA, and a human CD38 antigen. The invention also relates to such novel trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancers. The present invention relates to novel trispecific antibodies for the treatment of multiple myeloma.
Owner:ICHNOS SCIENCES SA

Wee1 protein kinase degradation agent and use thereof

A compound for degrading a Wee1 protein kinase or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of proliferative diseases.
Owner:HANGZHOU GLUBIO PHARM CO LTD

High drug loading formulations of encorafenib

PCT designated stage expiredWO2025003956A1Organic active ingredientsPowder deliveryDiseaseActive agent
This invention relates to high drug loading formulations comprising solid amorphous dispersions of encorafenib, together with one or more surfactants and polymers, and to methods of using such solid forms and pharmaceutical compositions in the treatment of proliferative diseases such as cancer.
Owner:PFIZER INC

Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications

Provided herein are an IL-2 fusion protein and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Owner:ANWITA BIOSCIENCES INC

Combination therapy for treating cancer

A method for treating proliferative diseases such as cancer in a subject by a combination therapy, which includes administering to the subject a pharmaceutical composition including a benzenesulfonamide derivative such as p-Toluenesulfonamide and at least one other therapeutic agents in a different classification of anticancer agents.
Owner:GONGWIN BIOPHARM CO LTD

Radiopharmaceutical MOFs for medical imaging

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.
Owner:ノード ファルマ アクシェセルスカープ

Application of gene recombinant of adenovirus vector and p53 gene

PendingCN119286933Ahigh titerGene therapy realityPeptide/protein ingredientsP53 proteinHuman tumorP53 protein
The invention relates to the technical field of gene engineering, and particularly discloses application of a gene recombinant of an adenovirus vector and a p53 gene, and application of the recombinant constructed by utilizing the adenovirus vector and the human p35 gene in preparation of drugs for treating proliferative diseases. The recombinant adenovirus is packaged by adopting an AdMax packaging system framework, the E1 / E2-deleted replication-deficient adenovirus is obtained through intracellular homologous recombination, recombinant virus particles with relatively high titer can be obtained, and the recombinant virus particles can have relatively high expression in cells with proliferative diseases, so that the recombinant adenovirus can be used for treating proliferative diseases. By means of the method, in-vivo transfer of the exogenous p53 gene and efficient expression of the exogenous p53 gene in hyperplasia tissue of a patient are achieved, so that the purpose of treatment is achieved, and gene treatment of hyperplasia diseases is achieved.
Owner:HUBEI HEGUANG NUOKANG BIOTECHNOLOGY CO LTD

Substituted phenyl oxooxazolyl piperidine dione compounds

Disclosed are compounds of Formula (I): (I) or stereoisomers, tautomers, or salts thereof, wherein R is defined herein. Also disclosed are methods of using such compounds to decrease the levels of Ikaros protein, Helios protein, Aiolos protein, and Eos protein; and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
Owner:BRISTOL MYERS SQUIBB CO

Egfr degraders, pharmaceutical compositions thereof, and uses thereof

The present disclosure provides a novel bifunctional compound that degrades EGFR, pharmaceutical compositions containing the compound, methods of preparation, and uses of the compounds of the disclosure to treat cell proliferative diseases, such as cancer.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD

Compound used as CDK4 kinase inhibitor and application thereof

The invention relates to a compound used as a CDK4 kinase inhibitor and application thereof. Specifically, the compound disclosed by the invention has a structure as shown in a formula II, and the definitions of all groups and substituent groups are described in the specification. The compound provided by the invention can be used as an inhibitor of cyclin-dependent kinase (CDK), is used for treating or preventing proliferative diseases (such as cancers), and is particularly used for regulating and treating related diseases caused by abnormal activity of the cyclin-dependent kinase (CDK). # imgabs0 #
Owner:TYK MEDICINES INC

Cross-specific antigen binding proteins (ABP) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof

The invention relates to antigen binding proteins, such as antibodies, that bind to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRBI) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA), which can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of LILRB receptors (interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. In particular, the invention provides products, compositions and methods for treating diseases using antigen binding proteins of LILRB1 and / or LILRB2, especially antigen binding proteins which while, preferably specifically, binding to LILRB1 and LILRB2, such as antigen binding proteins that further do not bind to, or bind with less affinity to, one or more LILRA receptor proteins (such as LILRA1 and / or LILRA3). Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.
Owner:IOMX THERAPEUTICS AG

PI3Kα Inhibitor and Method of Using the Same

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of the PI3Kα enzyme using the compounds and compositions of the present disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Kα signaling using the compounds and compositions of the present disclosure. Inhibitors of PI3Kα are considered to be particularly valuable in the treatment of proliferative diseases and other disorders. A plurality of inhibitors of PI3K (for example, taselisib, alpelisib, buparlisib, etc.) have been developed, but these molecules inhibit multiple class 1A PI3K isoforms.
Owner:RELAY THERAPEUTICS INC

Antibody-drug conjugates and uses thereof

The present invention relates to an antibody-drug conjugate, wherein the antibody specifically binds to the folate receptor a and the drug is preferably selected from among cytotoxic drugs. Such antibody-drug conjugates are particularly useful in the treatment of proliferative diseases, including cancers such as ovarian cancer, breast cancer and non-small cell lung cancer.
Owner:MABLINK BIOSCIENCE SAS